TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22453844

Group type: EXPERIMENTAL
Intervention: Deep water running (DWR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: General practice (GP) alone
Number of subjects: 58
Study: 20013055

Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (6 g daily from 12th-18th week of gestation until delivery)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no Chlorella supplementation)
Number of subjects: 70
Study: 18725823

Group type: EXPERIMENTAL
Intervention: NetLET (personalized e-mail from physician) in private access group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (mailed reminder letter from physician) in private access group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (mailed reminder letter from physician) in public access group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NetLET in public access group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NetLET in private access group
Number of subjects: 97
Study: 15692770

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 95
Study: 12796667

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1078
Study: 10505808

Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 1 second
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6% hydrogen peroxide
Number of subjects: 50

Group type: COMPARATOR
Intervention: EDTA solution (pH 7.4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saturated citric acid solution (pH 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 0.2, 0.4, or 0.6 seconds
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 0.8 seconds
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 1.2 and 1.4 seconds
Number of subjects: 50
Study: 9201757

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients with a history of long‐term institutionalization
Number of subjects: 72
Study: 1757172

Group type: EXPERIMENTAL
Intervention: Comprehensive program of smoking control, discouragement, and cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smoking cessation alone (control)
Number of subjects: 0
Study: 30235286

Group type: EXPERIMENTAL
Intervention: HIV-1 multiantigen DNA vaccine (HIV-MAG, 3000 μg) co-administered with IL-12 plasmid DNA adjuvant (0, 250, 1000, or 1500 μg) via electroporation.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: VSV-Gag vaccine (3.4 ⊆ 107 PFU) given at 6 months after the initial vaccination.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (12 participants).
Number of subjects: 88
Study: 27243762

Group type: EXPERIMENTAL
Intervention: Adaptive training group that received 12 sessions of training covering 3 inhibitory processes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group that received 4 sessions of mental health lectures
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adaptive training group
Number of subjects: 36
Study: 24458074

Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration
Number of subjects: 714

Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 714
Study: 22632452

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50, 100, 200, 300 mg daily or 300 mg twice daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo/Sitagliptin 100 mg daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo/Sitagliptin
Number of subjects: 198
Study: 20562541

Group type: EXPERIMENTAL
Intervention: Vibration therapy (RelaWave; Matsuda Micronics Corp, Chiba, Japan) applied for 15 minutes 3 times a day for up to 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (standard care according to PrU care guidelines)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vibration therapy
Number of subjects: 31
Study: 18097228

Group type: EXPERIMENTAL
Intervention: ECG evidence of IHD detected in HIV-infected adults
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Age > or = 60 years
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Current antihypertensive therapy
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Recruitment in Europe
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Recruitment in Asia
Number of subjects: 4831

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4831
Study: 17259790

Group type: EXPERIMENTAL
Intervention: One daily GH injection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two daily GH injections
Number of subjects: 18
Study: 12716484

Group type: EXPERIMENTAL
Intervention: IFN-beta1b treatment (16 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (8 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MS patients (both groups)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 10764849

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Presenting visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 or worse in both eyes
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of reduced vision
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Amblyopia as a cause of reduced vision
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Other causes of reduced vision
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Unexplained causes of reduced vision
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Myopia prevalence in 15-year-old females
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Myopia prevalence in 15-year-old males
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 5-year-old males
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 5-year-old females
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 15-year-olds
Number of subjects: 6134
Study: 9165428

Group type: EXPERIMENTAL
Intervention: Endovenous phenytoin (PHT) - two infusions (mean dosage of 18 mg/kg; mean time of 1 hr)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Endovenous phenytoin (PHT) - one infusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 1560798

Group type: EXPERIMENTAL
Intervention: Inositol (80 mg per kilogram of body weight per day)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 4091994

Group type: EXPERIMENTAL
Intervention: Phenytoin 0.5 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30671805

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clamp-crush group
Number of subjects: 72
Study: 29934764

Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Con‐vBFR
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR and Con‐vBFR
Number of subjects: 36
Study: 26868727

Group type: EXPERIMENTAL
Intervention: Preventive care (≥1 asthma maintenance visit/year)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Acute care (≥1 acute asthma visit/year)
Number of subjects: 948
Study: 24534386

Group type: EXPERIMENTAL
Intervention: Type 1 Modic changes
Number of subjects: 141

Group type: COMPARATOR
Intervention: Type 2 Modic changes
Number of subjects: 141

Group type: COMPARATOR
Intervention: Other degenerative manifestations
Number of subjects: 141
Study: 22932714

Group type: EXPERIMENTAL
Intervention: Trevo Retriever
Number of subjects: 178

Group type: COMPARATOR
Intervention: Merci Retriever
Number of subjects: 178
Study: 20171422

Group type: EXPERIMENTAL
Intervention: Test formulation (dispersible tablets) of MMF 1.0 g
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (capsules) of MMF 1.0 g
Number of subjects: 18
Study: 17607437

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with 24 blocks (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with 36 blocks (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with zero current intensity stimulation
Number of subjects: 45
Study: 16141440

Group type: EXPERIMENTAL
Intervention: Room air resuscitation (RAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% oxygen resuscitation (OxR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonasphyctic term newborns)
Number of subjects: 0
Study: 12173198

Group type: COMPARATOR
Intervention: 0.10% bupivacaine plus sufentanil 0.5 microgram ml-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine plus sufentanil 0.5 microgram ml-1
Number of subjects: 140
Study: 10460553

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.039 mg.kg‐1 bolus + 0.215 mg.kg‐1.h‐1 infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.05 mg.kg‐1 bolus + 0.275 mg.kg‐1.h‐1 infusion)
Number of subjects: 6
Study: 8849209

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BI) at 1 kHz
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BI) at 100 kHz
Number of subjects: 28
Study: 2211752

Group type: EXPERIMENTAL
Intervention: Lumbar plexus block with bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: No lumbar plexus block
Number of subjects: 20
Study: 339846

Group type: EXPERIMENTAL
Intervention: Topically applied caffeine 30%-hydrocortisone 0.5% in hydrophilic ointment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hydrocortisone 0.5% in hydrophilic ointment
Number of subjects: 83
Study: 30140069

Group type: EXPERIMENTAL
Intervention: Late surfactant treatment
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 209
Study: 28697127

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally 1 hour before ERCP
Number of subjects: 170

Group type: COMPARATOR
Intervention: Saline infusion only (control group)
Number of subjects: 170
Study: 25613468

Group type: EXPERIMENTAL
Intervention: PSA testing (intervention arm)
Number of subjects: 415000

Group type: COMPARATOR
Intervention: NHS prostate cancer risk management programme (control arm)
Number of subjects: 415000
Study: 24045411

Group type: EXPERIMENTAL
Intervention: Ready for Recess
Number of subjects: 98

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 98
Study: 22175055

Group type: EXPERIMENTAL
Intervention: 4 L polyethylene glycol (PEG)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: 2 L PEG + 20 mg bisacodyl
Number of subjects: 834

Group type: COMPARATOR
Intervention: 90 mL of sodium phosphate (NaP)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: PSMC + 300 mL of magnesium citrate (M)
Number of subjects: 834
Study: 18710606

Group type: EXPERIMENTAL
Intervention: EGCG (400 mg capsules, twice daily for 8 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (lactose, twice daily for 8 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 16359745

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol (4 drink equivalent)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 0.4 g/kg alcohol (2 drink equivalent)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12540352

Group type: EXPERIMENTAL
Intervention: Supervised inpatient rehabilitation in an orthopaedic hospital (Group A)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Supervised inpatient rehabilitation in a geriatric hospital (Group B)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No special rehabilitation, directly discharged home (Control Group C)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 145
Study: 10548187

Group type: EXPERIMENTAL
Intervention: CBF-targeted protocol
Number of subjects: 189

Group type: COMPARATOR
Intervention: ICP-targeted protocol
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 189
Study: 8752791

Group type: EXPERIMENTAL
Intervention: Emergency department‐based rapid rule‐out protocol (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine hospital care (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical control subjects (n = 160)
Number of subjects: 100
Study: 1853495

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 160

Group type: COMPARATOR
Intervention: Opioid (Pentazocine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 160
Study: 6395526

Group type: EXPERIMENTAL
Intervention: Bencyclan (2x 200 mg daily for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bencyclan
Number of subjects: 50
Study: 31672177

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 1-month DAPT
Number of subjects: 15991

Group type: COMPARATOR
Intervention: Conventional treatment (12-month DAPT followed by 12-month aspirin)
Number of subjects: 15991

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 15991
Study: 29196304

Group type: EXPERIMENTAL
Intervention: Early initiation of RRT (stage 2 AKI)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Delayed initiation of RRT (stage 3 AKI)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Early initiation of RRT
Number of subjects: 230

Group type: COMPARATOR
Intervention: Delayed initiation of RRT
Number of subjects: 230
Study: 26864363

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 8089

Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented group
Number of subjects: 8089
Study: 24656221

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 96
Study: 21945867

Group type: EXPERIMENTAL
Intervention: Restrained eaters who drank a milkshake
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline restrained eaters
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unrestrained co-twins
Number of subjects: 20
Study: 20568656

Group type: EXPERIMENTAL
Intervention: St. John's wort extract WS 5570 (600-1800 mg/day)
Number of subjects: 1661

Group type: COMPARATOR
Intervention: Paroxetine (20 or 40 mg/day)
Number of subjects: 1661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1661
Study: 17254329

Group type: EXPERIMENTAL
Intervention: Emulsified oil mixture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oil mixture
Number of subjects: 24
Study: 15580433

Group type: EXPERIMENTAL
Intervention: Maxout implant
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Maxout implant (intraoral placement)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Maxout implant (transnasal replacement)
Number of subjects: 3
Study: 11821608

Group type: EXPERIMENTAL
Intervention: Laparoscopic bipolar coagulation of uterine vessels (LBCUV) and laparoscopic supracervical amputation followed by trachelectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hysterectomy without LBCUV
Number of subjects: 64
Study: 10476242

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low doses of interferon beta-1a administered once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher, more frequent doses of interferon beta-1a
Number of subjects: 0
Study: 7562390

Group type: EXPERIMENTAL
Intervention: Repeated exposure to sexually violent films
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exposure to sexually violent films (comparison group)
Number of subjects: 0
Study: 2695566

Group type: EXPERIMENTAL
Intervention: Corticosteroids and anti-thymocyte globulin (ATG) for 2-4 weeks and prednisone for 2 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated IDD patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Corticosteroids and ATG
Number of subjects: 24
Study: 894798

Group type: EXPERIMENTAL
Intervention: Massive penicillin dosage (60 million units)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ticarcillin (200 mg. per kg.)
Number of subjects: 50
Study: 31150976

Group type: COMPARATOR
Intervention: Placebo group with PFOA concentration > median (4.9 ng/mL)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: PFOA
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: PFHxS
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: PFNA
Number of subjects: 888
Study: 28417914

Group type: COMPARATOR
Intervention: Above median serum 25(OH)D levels in the placebo arm
Number of subjects: 3377

Group type: COMPARATOR
Intervention: Serum IGFBP‐3 levels
Number of subjects: 3377
Study: 25348524

Group type: EXPERIMENTAL
Intervention: GSK2251052
Number of subjects: 14
Study: 23410265

Group type: EXPERIMENTAL
Intervention: Melodies presented in the same or similar articulation format from study to test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melodies rated as perceptually dissimilar due to articulation mismatch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall proportion of articulation mismatch
Number of subjects: 0
Study: 21884148

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Different clinical stages of dental procedures
Number of subjects: 20
Study: 19483232

Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid
Number of subjects: 73

Group type: COMPARATOR
Intervention: No tranexamic acid
Number of subjects: 73
Study: 17267928

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy with telephone support
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57
Study: 15097769

Group type: COMPARATOR
Intervention: Three scans per examination
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Five scans per examination
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Seven scans per examination
Number of subjects: 48
Study: 11698314

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 270
Study: 9135873

Group type: EXPERIMENTAL
Intervention: HIV protease inhibitor saquinavir (SQV) in combination with zidovudine (ZDV)
Number of subjects: 86
Study: 7520906

Group type: EXPERIMENTAL
Intervention: Risperidone (2, 6 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Risperidone (6, 10, 16 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Haloperidol (10 mg/day)
Number of subjects: 2
Study: 2544117

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inhaled salbutamol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral formoterol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oral salbutamol
Number of subjects: 9
Study: 1092411

Group type: EXPERIMENTAL
Intervention: Intermittent electrical calf muscle stimulation during surgery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin calcium 5000 IU every eight hours for six days
Number of subjects: 3

Group type: COMPARATOR
Intervention: No specific prophylaxis
Number of subjects: 3
Study: 29917096

Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training with experience sampling (MMT-ES)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Experience sampling only (ES)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Both groups (MMT-ES and ES)
Number of subjects: 325
Study: 31387868

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Package (PRT‐P)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 48
Study: 26951348

Group type: EXPERIMENTAL
Intervention: Pilates exercise training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standardized physical therapy
Number of subjects: 45
Study: 23332882

Group type: EXPERIMENTAL
Intervention: Solifenacin 5mg once daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5mg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22150035

Group type: EXPERIMENTAL
Intervention: Combination-therapy group (rifapentine 900 mg + isoniazid 900 mg for 3 months)
Number of subjects: 7731

Group type: COMPARATOR
Intervention: Isoniazid-only group (isoniazid 300 mg for 9 months)
Number of subjects: 7731
Study: 19458028

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-Fat (HF) meal
Number of subjects: 27
Study: 22184370

Group type: EXPERIMENTAL
Intervention: AMG 386 10 mg/kg QW plus paclitaxel
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: AMG 386 3 mg/kg QW plus paclitaxel
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 161
Study: 16006832

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0